Vector-borne diseases (VBDs) constitute a significant public health challenge in India, contributing to morbidity and mortality rates. This article aims to provide healthcare professionals with a comprehensive review of the prevalence and impact of VBDs in India.
VBDs, including malaria, dengue, and chikungunya, are endemic in India. The World Health Organization (WHO) reports that India accounts for 4% of global malaria cases. Dengue, with its rapid urban spread, has seen a drastic increase, with over 100,000 cases reported annually. Chikungunya, although less prevalent, has caused significant outbreaks in recent years.
The impact of VBDs on India's public health system is profound. Beyond the immediate health implications, these diseases have socio-economic consequences, burdening the healthcare system and affecting productivity due to illness-related work absences. Additionally, the cost of managing and controlling these diseases is substantial, straining limited resources.
India's diverse geography and climate, coupled with high population density, create a conducive environment for vectors. This, coupled with inadequate public health infrastructure, exacerbates the VBD challenge. However, opportunities for improvement exist. Enhancing disease surveillance, improving diagnostic capabilities, and strengthening vector control programs can significantly mitigate the impact of VBDs.
Understanding the prevalence and impact of VBDs is crucial for healthcare professionals in India. This knowledge can guide disease control strategies, inform policy-making, and enable better patient care. As we continue to grapple with these diseases, a comprehensive, multi-sectoral approach that includes improved surveillance, diagnostics, vector control, and community engagement is imperative to reduce the burden of VBDs in India.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation